Eli Lilly Secures Chinese Approval for Early Symptomatic Alzheimer's Disease Medicine
Eli Lilly and Co's potential blockbuster new drug donanemab has been approved for sale in China! It is used for treating Alzheimer's disease.
On December 18, Eli Lilly and Co (LLY.US) just announced that its Class 1 new drug donanemab injection application has been approved by the National Medical Products Administration of China (NMPA).
Express News | Lilly's Kisunla™ (Donanemab-Azbt) Approved in China for the Treatment of Early Symptomatic Alzheimer's Disease
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
Peering Into Eli Lilly's Recent Short Interest
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
